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EBV is a double-stranded DNA virus ofthe herpes-virus family and is thecausa-
tive agentofinfectious mononucleosis, AfricanBurkitt'slymphoma, andnasopharyn-
geal carcinoma(1). After primary infection involving thenasopharynx, EBV remains
latent in epithelial cells ofthe normal salivary gland and periodically becomes reac-
tivated (2, 3). The frequency ofEBV reactivation, as evidenced by infectious virus
in saliva, is elevated in patients with lymphoproliferative diseases and in transplant
recipients receivingimmunosuppressive medications(4-6). Inthese conditions, there
is frequently an increased number ofcirculating EBVtransformed lymphocytes, as
detected by their spontaneous outgrowth in vitro (7, 8). Since EBVinfected cells
are controlled by T cell immune responses (9), accurate measurement ofcells con-
taining viral DNA in the circulationorat the site oflatency (i.e., the salivary gland)
may provide an important method to assess immune competence in vivo and early
detectionofEBVrelated lymphomas/carcinomas that arise in these individuals (10).
We have used polymerase chain reaction (PCR)' to provide a rapid, accurate
method fordetection ofEBV DNA inPBMC and in tissue biopsies. We have chosen
to study patients with Sjogren's syndrome (SS), an autoimmune disease involving
lacrimal and salivary glands (11, 12), since these patients have increased frequency
oflymphoma (13, 14) and frequently undergo salivary gland biopsies for diagnostic
purposes (15). We found an increased level ofEBV DNA in the salivary gland biop-
sies ofthese patients, suggesting that this virus is reactivated in vivo and may pro-
vide a target for the chronic "autoimmune" attack on the salivary gland.
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Materials and Methods
Polymerase Chain Reaction.
￿
PCR is a technique basedon the binding ofspecific oligonucle-
otide primers to defined DNA sequences and amplification ofthe DNAbetweentheseprimers
(16-18); PCR has been greatly simplified by automatedprocedures that use thethermostable
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enzyme DNA polymerase (19). Specific primers and probes were synthesized based on the
published DNA sequences ofBaer et al. (20), corresponding to the Bam W and Barn M regions
of the EBV genome (Table I). The Barn W region was chosen as a target gene since this
DNA segment is reiterated 10 times (21) and thus should provide a more readily detected
sequence than a single copy viral gene. PCR reaction mixtures contained 1 hg of peripheral
blood or salivary gland genomic DNA, 50 mM KCL, 10 mM Tris (pH 8.4), 2.5 MM MgC12,
each primer (Table I) at 100 pM, each dNTP (dATP, dCTP, dGTP, TTP) at 200 AM, gelatin
at 200 hog/ml, and 2.5 U of thermostable Taq polymerase (Cetus Corp.). The amplification
was carried out as previously described (19) with a DNA Thermal Cycler (Perkin-Elmer Cetus,
Norwalk, CT). After the amplification steps, one-tenth of the reaction mixture was removed,
the NaCI concentration was adjusted to 0.15 M, and it was analyzed by Southern blot method
with a 32P-labeled oligonucleotide probe (Table I) at 42°C for 1 h. The filter was washed
twice with 6 x SSPE (1 x SSPE: 0.18 M NaCl, 10 mM NaH2PO4, 1 mM EDTA, pH 7.4),
0.1% SDS at room temperature, followed by wash for 10 min at 55°C (for Barn W) or 60°C
(for BMRFl and BMLF1) and autoradiography for 3 h at -80°C with a single intensifying
screen. The intensity of the signal obtained with each oligonucleotide probe was determined
by densitometry tracing of the autoradiograph.
All DNA samples were initially screened for EBV DNA using the Bam W primers and
35 cycles of PCR amplification. If the sample had detectable viral DNA, then 1 Rg of the
original tissue sample DNA was again amplified in the presence of other primers for EBV
(as described above) plus primers for the single copy gene HLA-DQa (22). Aliquots were
removed after 20, 25, 30, 35, and 40 cycles of amplification, separated on agarose gels, and
analyzed by Southern blots with probes specific for EBV or HLA-DQa (22). Densitometry
tracing was again performed to quantitate the relative intensity of the band. Standard mix-
tures of viral DNA plus uninfected cell DNA were run in parallel with the clinical samples.
Tissue samples that did not contain detectable EBV were re-analyzed with the HLA-DQa
primers and 35 cycles of PCR to insure that the DNA did not contain inhibitors of the PCR
reaction.
Sample Preparation.
￿
Genomic DNA was prepared from PBMC of patients with SS and
of age- and sex-matched normal controls (23). In addition to PBMC samples, DNA was ex-
tracted from salivary gland (SG) biopsy tissue samples from SS patients, from "normal" sali-
vary gland removed at autopsy, and from the histologically normal margins of biopsies re-
moved for SG adenomas. DNA was prepared from these tissues by lyophilization for 16 h,
digested with RNAase (10 mg/ml) for 2 h, and proteinase K (1 mg/ml) for 16 h at 37°C,
followed by phenol extraction and ethanol precipitation (24). This method ofDNA prepara-
tion avoids use of tissue homogenizers, a possible source for cross-contamination of tissue
TABLE I
Sequence of Primers and Probes
Region Sequence -
Location in
genome ofEBV
1 . Barn W
TC60 Primer CCAGAGGTAAGTGGACTT 1396-1416
TC61 Primer GACCGGTGCCTTCTTAGG 1520-1503
TC62 Probe TTCTGCTAAGCCCAAC 1424-1439
11. BMRF1
TC67 Primer CAGGCTTCCCTGCAATTTTACAAGCGG 80220-80246
TC69 Primer CCCAGAAGTATACGTGGTGACGTAGA 80507-80482
TC68 Probe GATGATAAGGTGTCCAA 80295-80311
III. BMLF1
TC70 Primer CTTGGAGACAGGCTTAACCAGACTCA 83520-83545
TC72 Primer CCATGGCTGCACCGATGAAAGTTAT 83874-83850
TC71 Probe TCTGGAGCCACGAGAT 83679-83694sample DNA. All buffers and pipettes used for PCR were carefully isolated from contact
with bacteria that might contain plasmids with EBV DNA inserts .
Results
Detection ofEBVDNA byPCR.
￿
Primers were synthesized corresponding toa reiter-
ated gene (Barn W) and single copy genes (BMRF1 and BMLF-1) of the EBV ge-
nome (Table I), and to theHLA-DQa gene (22) . Gene segments corresponding to
each oftheseprimers were amplified usingPCR(Fig. 1A) . The reiterated viralDNA
sequence (Barn W) was detected at a lower number of cycles than the single copy
viral genes or the single copy HLA-DQa gene (DQa) .
The sensitivity of PCR to detect EBVinfected cells among uninfected cells was
assessed by mixing DNA from an EBVtransformed cell withDNA from an unin-
fected cellDNA under conditions where the total amount ofDNA remained con-
stant (Fig . 1 B) . Each curve represents a decreased amount of viral DNA diluted
into uninfected cellDNA. Aliquots were removed after varying numbers of cycles
ofPCR, transferred to nylon membranes, probed with "P-labeled oligonucleotides
specific forBarn W, andquantitatedby densitometry tracing ofthe autoradiograph .
An increasednumber ofPCR cycles were required to obtain the same relative signal
when a lower amount ofEBVDNA was present in the original mixture (Fig . 1 B) .
Based on these reconstruction experiments, it was possible to detect approximately
one EBV transformed cell per 100,000 uninfected cellDNA equivalents (Fig . 1 B) .
As an internal control, we also measured the content ofa single copy human gene
(DQa) in each sample . Since the total amount ofhuman genomic DNA remained
constant in each sample, an identical pattern of DQa amplification was noted for
each dilution ofviralDNA. This pattern ofDQa amplification was identical to that
described in Fig . 1 A, indicating that the presence ofviral primers did not influence
the amplification of DQa DNA (data not shown) . Similarly, the presence of DQa
primers did notinfluence the amplification ofviralDNA. Thus, comparison ofreac-
tivity with viral-specific probes and single copy human gene probes makes it pos-
sible to approximate the content of viral DNA in an unknown sample (see below) .
FIGURE 1 .
￿
(A)DNA from anEBVtransformed
cell line (Novako/EBVI, a diploid cell line that
containing 2-3 copies ofEBVDNA per cell) (25)
was amplified by PCR methods using primers
specific for the EBVencoded genes BamW (A),
BMRF1 (/), or BMLF-1 ([3) (Table I). Also,
primers specific for theHLA-DQa (" ) gene (22)
were included as an internal control in each reac-
tion mixture . 1 Wg of Novako/EBVI DNA was
included with 100 pm of each primer and 2 .5 U
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Taq polymerase per reaction mixture . After a
varying number ofPCR cycles, an aliquot ofthe
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￿
reaction mixture was applied to agarose gels,
transferred to nylon membrane and reactedwith
12P-labeled EBV or DQa-specific oligonucleo-
tides . The intensity of reaction was quantitated using a densitometer . Peak areas are given as relative
units . (B) Reconstruction experiments to detectEBVDNA. DNA from an uninfectedT cell line (RPMI
8402) was mixedwithDNA (1 kg) from anEBVtransformed cell line (Novako/EBV 1) and was amplified
by 10-80 cycles of thePCR with the BarnW primers . The amount of added viralDNA included 1 jug
Novako/EBVI DNA (A), 100 ng (/), 1 ng (p), and 10 pg (") .
10
8
6
2
0
SAITO ET AL .
￿
21932194
￿
EPSTEIN-BARR VIRUS DNA IN SJOGREN'S SYNDROME
FIGURE 2 . Southern analysis of PCR
amplified genomic DNA with the EBV
Barn W probe (A) and EBV BMRF1
probe (B) . PCR amplification performed
as described below. (Lanes 1 and 2)DNA
fromPBMC from patients with SS; (lanes
3 and 4)DNA from normalPBMC ; (lanes
5-7)DNA from SSSG; (lanes 8-10)DNA
from normal SG .
Increased Level ofEBVDNA in Patient Samples.
￿
After35 cycles ofPCRamplification
usingthe Bam W-encoded primers and "P-labeled BarnW oligonucleotide probe,
we found significant reactivity in the PBMC DNA of 6/33 SS patients (Fig . 2 A,
lanes 1 and 2) . Salivary gland biopsies from seven of nine SS patients contained
EBVDNAusing the BarnW primers and probes (examples sho-s .nin Fig . 2A, lanes
5-7) . Specific amplificationwasalso achieved usingBMFR 1 primers in theseDNA
samples (Fig. 2 B, lanes 1-2, and 5-7) . The specific reactivity with BamW and
BMRF1 primers was confirmed using an additional set ofprimers/probes from the
BMLF1 region ofEBV(Table I) (data not shown) . In comparison, normal salivary
gland biopsy DNA exhibited reactivity in only 2 of 15 cases when a similar number
of cycles of amplification were used (Fig. 1,A andB, lanes 8-10) . Finally, EBVDNA
was detected in only 3 in 50 normal PBMC andin0 in 10 normal lymph node (LN)
samples . These results are summarized in Table II . The frequency of SS salivary
glands containing EBV DNA (78%) was higher than the frequency of SS PBMC
containing EBV (18%) or from histologically normal salivary glands (13%) (p <
0.001) .
TABLE II
Summary ofPCR Detection ofEBV DNA in Clinical Samples
The density of autoradiographic band after a limited number ofPCR cycles corresponded
to 10-20 copies ofDNA per 10 5 cells equivalents indicated by + + + ; 5-10 copies EBV ge-
nome per 10 5 genomes ( + + ) ; 1-5 copies EBV per 105 cells ( + ) ; or <1 copy EBV per 10 5
cells (- ) .
` SG refers to DNA from salivary gland, LN from lymph node, and PBMC from PBMC .
SS refers to patients with Sjogren's Syndrome .
Barn W primer BMRF-1 primer
Percent Percent
Clinical samples" n + + + + + + - positive + + + + + + - positive
SS SG 9 2 2 3 2 78 2 2 3 2 78
Normal SG 15 0 0 2 13 13 0 0 2 13 13
SS PBMC 33 3 0 3 27 18 1 2 1 29 12
Normal PBMC 50 0 0 3 47 6 0 0 5 45 10
Normal LN 10 0 0 0 10 0 0 0 0 10 0SAITO ET AL.
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Discussion
We found increased levels of EBV DNA in SG biopsies from patients with SS,
in comparison tobiopsies from normal salivary glands (autopsy), patientswith other
autoimmune disorders, orpatients withbenign SGadenomas. We estimatethatnormal
SG contained <1 copy ofEBV DNA per 100,000 cell DNA equivalents; in contrast,
the SS biopsiescontained20 ormore EBV copies per 100,000 cell DNAequivalents.
These results suggest that EBV latency in the normal SG is maintained through
infection of a small number of epithelial cells and that EBV is reactivated in the
SG of SS patients (3, 25). The increased content ofEBV DNA in the SS salivary
gland may represent a primary defect (i.e., an inherited inability to eliminate EBV
infected cells, as occurs in some immunodeficiency diseases) (4) ora secondary de-
fect (i.e., the decreased ability to respond effectively to EBV as an acquired conse-
quence of immune dysfunction) (6). Further characterization of the salivary and
lacrimal gland T cells in vitro will be required to help evaluate these possibilities.
Since EBV antigens are known to induce very strong T cell immune responses (26,
27) and epithelial cells of SS patients are intensively HLRDR+ (in contrast to
normal SG cells that lack HLA-DR) (28), it islikely thatimmune responsesdirected
against EBVinfected epithelial cells play a role in the perpetuation ofSG destruc-
tion in SS patients. In this regard, SS may serve as a prototype human disease for
studying the interaction of genetic and environmental factors in chronic autoim-
mune disease.
To analyze the small tissue biopsies from these patients, we used PCR methods.
This study extends the use of PCR for clinical diagnosis in several regards. First,
we were able to estimate the content ofEBV DNA in comparison to cellular DNA.
Thiswasdoneby including primers forboth viral DNAand forasingle copy human
gene (i.e., HLA- DQa). This approach is in contrast to previous studies wherePCR
has been used to detect the presence/absence of viruses such as human im-
munodeficiency virus, hepatitis virus, or rhinovirus (29-32), where viral presence
is sufficient to allow disease diagnosis. Inthe case ofEBV, virtually alladults harbor
the virus at low levels and only increased levels are likely to be associated with dis-
ease (4, 6, 10). Therefore, it is necessary to quantitate the amount of EBV DNA
and we have used a method for comparison to a single copy gene (i.e., HLA-DQa).
This method also ensures that the DNA sample does not contain inhibitors ofPCR
that could lead to artefactually negative results ofviral detection. Second, a poten-
tial problem in the use ofa sensitive technique such as PCR is possible contamina-
tionofthe tissue sample bysmall amountsofviral DNAduring sample preparation.
We and others (33) have noted that contamination ofsamples may occur at the step
oftissue homogenization to make DNA, perhaps due to the need to "handle" tissues
or due to "carryover" of trace amounts of DNA from prior samples. This problem
has been minimized by placing the sterile tissue sample immediately into a sterile
plastic tubewhere itremainsduring lyophilization to dryness, digestionwithRNAase
and proteinase K, and phenol extraction. This modification has significantly de-
creased the frequency ofartefactual false positives, as well as allowing more rapid
processing ofa larger number ofclinical samples. These methods of sample prepa-
ration also may prove useful in analyzing tissue biopsies from other autoimmune
disease (i.e., diabetes, thyroiditis, polymyositis, systemic lupus erythematosus) where
only small tissue samples are accessible early in the course of disease.2196
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Several different methods have been used to quantitate EBV DNA in patient samples.
Tosato et al. (7) used the method of spontaneous outgrowth of lymphoblastoid cell
lines in the presence of cyclosporin A to estimate the frequency of EBVtransformed
lymphocytes in vivo. Other studies have used cocultivation with newborn lympho-
cytes (34) or in situ hybridization with labeled EBVspecific probes (35). PCR offers
several advantages over detection of EBV by spontaneous outgrowth (7) or co-
cultivation methods (34). First, PCR detection of viral DNA is not influenced by
the endogenous immune response that may inhibit outgrowth of viral transformed
cells in vitro (27). Second, DNA amplification will detect infected cells that are not
actively shedding virus (i.e., a requirement for co-cultivation assays). Third, PCR
is not dependent on cell suspensions required for in vitro assays and is suitable for
small tissue biopsies (37) such as SG. Other methods such as in situ hybridization
(35) or immunohistology (36) also may be used for viral detection in tissue samples,
but the enumeration of rare infected cells (i.e., 1 in 105) is quite difficult and is often
limited by nonspecific cross-reactions of antibodies or DNA probes .
Summary
Polymerase chain reaction has been used to detect increased levels of EBV DNA
in salivary gland (SG) biopsies and PBL from patients with Sjogren's syndrome (SS).
These results suggest that EBV, which has a normal site oflatency in a small number
of SG epithelial cells, may be reactivated in SS patients and provide a target for
immune attack. The great sensitivity of polymerase chain reaction (PCR) and the
ability to analyze very small tissue biopsies (37) make this technique well suited for
clinical diagnosis. Specific methods to prevent artefactual contamination of tissue
biopsy DNA with viral DNA of other samples (i.e., lyophilization of samples before
DNA extraction) and the use ofan internal positive control (i.e., inclusion ofprimers
for a single copy human gene) during PCR amplification are presented. Since EBV
reactivation occurs with markedly increased frequency in patients with lymphoprolifer-
ative and immunodeficiency diseases, as well as transplant recipients receiving cy-
closporin A (10), rapid methods of viral detection such as PCR may allow better
monitoringof medications and early detection ofEBVrelated lymphomas that may
arise in these patients.
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